JBM (Healthcare) Limited (2161.HK)
HKD 2.09
(6.09%)
HKD 2.09
(6.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 174.2 Million HKD | 132.94% |
| 2022 | 67.77 Million HKD | 86.38% |
| 2021 | 36.36 Million HKD | -48.72% |
| 2020 | 70.91 Million HKD | 36.77% |
| 2019 | 51.84 Million HKD | -22.06% |
| 2018 | 66.52 Million HKD | 24.21% |
| 2017 | 53.55 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | 78.88 Million HKD | 0.0% |
| 2023 FY | 157.86 Million HKD | 132.94% |
| 2023 Q4 | 88.4 Million HKD | 0.0% |
| 2022 FY | 67.77 Million HKD | 86.38% |
| 2022 Q4 | 41.85 Million HKD | 0.0% |
| 2022 Q2 | 25.91 Million HKD | 0.0% |
| 2021 Q2 | 14.64 Million HKD | 0.0% |
| 2021 FY | 36.36 Million HKD | -48.72% |
| 2021 Q4 | 21.71 Million HKD | 0.0% |
| 2020 Q2 | 40.25 Million HKD | 0.0% |
| 2020 Q4 | 30.66 Million HKD | 0.0% |
| 2020 FY | 70.91 Million HKD | 36.77% |
| 2019 FY | 51.84 Million HKD | -22.06% |
| 2018 FY | 66.52 Million HKD | 24.21% |
| 2017 FY | 53.55 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -21.811% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 93.459% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 2234.342% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -326.137% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 433.835% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -383.339% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 43.865% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 363.763% |
| SSY Group Limited | 1.63 Billion HKD | 89.371% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 47.706% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 98.566% |